Stapokibart for non-allergic rhinitis with eosinophilia
Treatments studied
Part of Ear, nose & throat, Immune system & allergy, Lungs & breathing clinical trials.
This trial tests an investigational drug called Stapokibart (CM310) for people with non-allergic rhinitis with eosinophilia syndrome (NARES). It aims to see if the drug can better control persistent nasal symptoms like congestion, runny nose, and sneezing when standard treatments aren't enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have a diagnosis of non-allergic rhinitis with eosinophilia syndrome (NARES) for at least 2 years, with nasal symptoms like congestion, runny nose, sneezing, or loss of smell.
- You must have had a negative allergy test (skin prick test and blood test for specific IgE) and evidence of eosinophils in your nasal mucus.
- Your nasal symptoms must be moderately severe (score of 4 or more on a symptom scale) even after using nasal steroids or other medications.
- You must be willing to use effective birth control during the study and for 3 months after the last dose.
- You cannot have asthma that is poorly controlled (FEV1 less than 60%) or require high-dose inhaled steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
Stapokibart is a new injection that works on a key pathway involved in allergy symptoms. This study will test if this once-every-two-week shot can help reduce runny nose, sneezing, and itchy eyes in people with allergic rhinitis (hay fever).
This study tests a new injection called Stapokibart for people with seasonal allergic rhinitis (hay fever triggered by pollen or mold). The goal is to see if it helps control symptoms like sneezing, runny nose, and itchy eyes.
This trial tests whether a new medication called stapokibart, given before endoscopic sinus surgery, helps treat chronic rhinosinusitis with nasal polyps (a condition causing persistent nasal congestion, polyps in the sinuses, and loss of smell). The goal is to see if this medication reduces symptoms and improves surgical outcomes.
This trial tests if a new drug (Stapokibart) combined with a sinus surgery improves symptoms like nasal congestion, discharge, and loss of smell in people with type 2 chronic sinusitis.
This study tests a new injectable medication called stapokibart to help teenagers with seasonal allergic rhinitis (hay fever). The goal is to see if this treatment reduces allergy symptoms like sneezing, congestion, and itchy eyes during allergy season.
This trial tests an experimental medication (Stapokibart) for children ages 2 to 11 with moderate-to-severe eczema that hasn't improved with topical creams. The goal is to see if the new treatment can help control their symptoms.
Hear when a new Non-Allergic Rhinitis With Eosinophilia Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.